Back to top
more

Align Technology (ALGN)

(Delayed Data from NSDQ)

$212.15 USD

212.15
651,165

+1.37 (0.65%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $211.69 -0.46 (-0.22%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Dental Supplies

Zacks News

Why Brookdale Senior Living (BKD) Could Be Positioned for a Slump

One stock that you may want to consider dropping is Brookdale Senior Living Inc. (BKD), which has witnessed a significant price decline in the past four weeks.

    AmerisourceBergen's PharMEDium Slows Down, Competition Rife

    AmerisourceBergen Corporation (ABC) is facing immediate integration risks from its acquisition of PharMEDium. Also, competition in the generic space raise concern.

      STAAR Surgical (STAA) Catches Eye: Stock Moves 8.3% Higher

      STAAR Surgical Company (STAA) moved big last session, as its shares jumped over 8% on the day.

        Zacks.com featured highlights: Gray Television, Align Technology, SolarEdge Technologies, Nova Measuring Instruments and Brooks Automation

        Zacks.com featured highlights: Gray Television, Align Technology, SolarEdge Technologies, Nova Measuring Instruments and Brooks Automation

          BioScrip (BIOS) Gains on CORE Initiatives, Competition Rife

          The company achieved annualized supply chain improvement since the acquisition of Home Solutions.

            OPKO Health (OPK) Posts Narrower-than-Estimated Loss in Q2

            OPKO Health (OPK) posted lackluster Q2 numbers due to rising operating expenses owing to investment associated to the launch of RAYALDEE, and consistent investment in the pharmaceutical pipeline.

              Kevin Cook headshot

              The $200 Club: Will Facebook Beat Alibaba There First?

              When you find great fundamental growth stories that institutions must own, you can buy and trade them for a long time in a bull market.

                CVS Health Grows on Specialty Pharmacy amid Retail Woes

                CVS Health (CVS) rides on strong PBM selling season. Poor Retail/ LTC business and escalating expenses are drag on the bottom line.

                  Chimerix (CMRX) Q2 Loss Narrower than Expected, Revenues Down

                  Chimerix (CMRX) revenues in Q2 were hurt by reduced reimbursable expenses related to the company's BARDA developmental contract.

                    Haemonetics Banks on Solid Plasma & Haemonetics Management

                    Despite encouraging growth at the Plasma and Haemonetics Management franchises, the underperformance at the BloodCenter franchisee was quite a dampener for Haemonetics (HAE).

                      Bio-Techne (TECH) Beats Earnings, Revenue Estimates in Q4

                      Bio-Techne (TECH) rides high on strength in all three segments in Q4. Also, the company is focusing on product innovation through research and development.

                        Nevro's (NVRO) Q2 Loss Wider than Expected, Revenues Beat

                        Nevro's (NVRO) topline gains on continued global adoption of HF10 therapy. Rising operating expenses are major concerns.

                          Focus on These 5 Top-Ranked Profitable Stocks in August

                          Higher net income ratio usually implies a company's ability to generate ample revenue and successfully manage all its business functions.

                            STERIS (STE) Beats on Q1 Earnings & Revenues, Margins Up

                            STERIS' (STE) organic growth performance was strong across most segments in Q1. Robust cash position was another upside.

                              BioScrip (BIOS) Q2 Loss Wider Than Expected, Revenues Miss

                              BioScrip (BIOS) continues to disappoint in Q2 mainly due to its strategic shift to focus on growing its core revenue mix.

                                BioTelemetry (BEAT) Q2 Earnings Top, Revenues Meet Estimates

                                BioTelemetry (BEAT) rides high on all its segments in Q2. The company is also putting in efforts in product innovation through research and development.

                                  Myriad Genetics (MYGN) Beats on Q4 Earnings & Revenues

                                  Myriad Genetics (MYGN) rides high on strength in Molecular diagnostics with significant contributions from GeneSight. Also, hereditary cancer testing continues to witness sequential growth.

                                    Penumbra (PEN) Loss Meets Estimates, Revenues Beat in Q2

                                    Penumbra (PEN) witnessed strong growth across all its geographies and product lines in Q2. New product launches raise hope.

                                      CVS Health (CVS) Q2 Earnings Beat, '17 Guidance Narrowed

                                      CVS Health continues to grow (CVS) with Pharmacy Services business. However, its Retail/LTC sales drop.

                                        Henry Schein (HSIC) Q2 Earnings & Revenues Beat, View Intact

                                        Henry Schein (HSIC) maintained its stellar performance in Q2 as well, courtesy of strength in all of its business segments.

                                          Orthofix (OFIX) Earnings Meet, Sales Beat Estimates in Q2

                                          Orthofix (OFIX) rides high on strength in Biologics and Spine Fixation businesses. Moreover, raised full-year 2017 guidance buoys optimism.

                                            Haemonetics (HAE) Q1 Earnings Beat, Revenues Miss Estimates

                                            Haemonetics (HAE) rides high on Plasma and Haemonetics Management franchises strength in Q1.

                                              Bio-Rad (BIO) Misses Q2 Earnings & Sales, Margin Declines

                                              Bio-Rad's (BIO) sales declined on ERP-related disruption. Margin pressure continues.

                                                Cardiovascular Systems Rides on Innovation Amid Several Woes

                                                Cardiovascular Systems' (CSII) low operating expenses and strong revenue performance contributed to the upside in Q2 earnings.

                                                  Pacific Biosciences (PACB) Posts Wider-than-Expected Q2 Loss

                                                  Pacific Biosciences (PACB) posted a dull quarter with revenues declining in Q2. However, the company continues to anticipate 35% to 45% growth in product and service revenues for the year.